SIRT1 and neurodegenerative disease: We realize the limited ability of animal models to predict efficacy for complex neurodegenerative diseases such as AD47, however, the preclinical data showing enhancement of the neurotrophic SirT1 and improvement in memory suggests that DDL-218 has the potential to address pathology-related alterations in synaptic plasticity, neuronal function and pathways, leading to improvement in cognitive function, which could complement the lack of memory improvement achieved by Aβ-targeted antibodies.